<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118893</url>
  </required_header>
  <id_info>
    <org_study_id>V15Sep21</org_study_id>
    <nct_id>NCT05118893</nct_id>
  </id_info>
  <brief_title>Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend</brief_title>
  <acronym>RAFT-AF Extend</acronym>
  <official_title>Randomized Ablation-based Atrial Fibrillation Rhythm-control Versus Rate-control Trial in Patients With Heart Failure and High-burden Atrial Fibrillation Extend</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthony Tang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an extended follow up study of the original RAFT-AF Study. The RAFT-AF study was a&#xD;
      multi-centre randomized controlled trial with a prospective randomized open blinded endpoint&#xD;
      trial (PROBE) design. Patients were randomized to either catheter ablation-based rhythm&#xD;
      control of AF as compared to rate control of AF&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RAFT-AF Extend Trial is a continued follow up of patients enrolled in the original&#xD;
      RAFT-AF Study (ClinicalTrials.gov, NCT01420393), which evaluated whether ablation-based&#xD;
      rhythm-control compared to rate-control improves clinical outcomes in patients with heart&#xD;
      failure and atrial fibrillation. It was a randomised, open-label clinical trial, with blinded&#xD;
      endpoint adjudication, conducted in 21 institutions in four countries. Patients with atrial&#xD;
      fibrillation, New York Heart Association class II-III heart failure, and elevated NT-proBNP&#xD;
      were included. Patients were randomized (1:1) to ablation-based rhythm-control or&#xD;
      rate-control, stratified by left ventricular ejection fraction (≤45% and &gt;45%).&#xD;
      Ablation-based rhythm-control consisted of pulmonary vein isolation in paroxysmal atrial&#xD;
      fibrillation, and additional ablation for persistent atrial fibrillation. Rate-control&#xD;
      included AV-nodal blocking agents and AV node ablation with permanent pacing. The primary&#xD;
      outcome was a composite of mortality and heart failure events, with a minimum follow up of&#xD;
      two years. Secondary outcomes included left ventricular ejection fraction, quality of life,&#xD;
      six-minute walk test and NT-proBNP. The primary analysis was intention-to-treat. From&#xD;
      December 1, 2011, to January 20, 2018, 411 patients were randomised to ablation-based&#xD;
      rhythm-control (n=214) or rate-control (n=197). The primary outcome occurred in 50 (23·4%)&#xD;
      patients in the ablation-based rhythm-control group and 64 (32·5%) patients in the&#xD;
      rate-control group (hazard ratio 0·71 95% CI (0·49, 1·03), p=0·066). Quality of life,&#xD;
      six-minute walk distance, left ventricular ejection fraction, and NT-proBNP demonstrated&#xD;
      greater improvements in the ablation-based rhythm-control group.&#xD;
&#xD;
      In patients with high burden atrial fibrillation and heart failure, there was no&#xD;
      statistically significant reduction of all-cause mortality or heart failure events with&#xD;
      ablation-based rhythm-control versus rate-control. With the hazard ratio equivalent to the&#xD;
      minimal clinically important difference and the result near statistical significance, there&#xD;
      is a probable clinically important benefit of ablation-based rhythm-control over&#xD;
      rate-control.&#xD;
&#xD;
      This RAFT-AF Extend study is to extend follow up in RAFT-AF patients for an additional 24&#xD;
      months in order to have sufficient power to definitely determine if ablation-based rhythm&#xD;
      control of atrial fibrillation is superior to rate control for the reduction of the primary&#xD;
      outcome of all-cause mortality or heart failure event in patient with atrial fibrillation and&#xD;
      heart failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of mortality and Heart Failure Events</measure>
    <time_frame>24 months</time_frame>
    <description>Death or HF Event ( admit &gt; 24 hrs or urgent out patient or ER visit for IV diuretics)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Events</measure>
    <time_frame>24 months</time_frame>
    <description>HF Event ( admit &gt; 24 hrs or urgent out patient or ER visit for IV diuretics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life MLHFQ</measure>
    <time_frame>24 months</time_frame>
    <description>Minnesota Living with Heart Failure Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life AFEQT</measure>
    <time_frame>24 months</time_frame>
    <description>AF Effect on Quality-of-life,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life EQ5D</measure>
    <time_frame>24 months</time_frame>
    <description>EuroQol- 5 Dimension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute hall walk</measure>
    <time_frame>24 months</time_frame>
    <description>six minute hall walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>24 months</time_frame>
    <description>NT-proBNP blood meaure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV function</measure>
    <time_frame>24 months</time_frame>
    <description>Echo measure Left ventricular ejection fraction</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">311</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ablation-based rhythm-control</arm_group_label>
    <description>Ablation-based rhythm-control consisted of pulmonary vein isolation in paroxysmal atrial fibrillation, and additional ablation for persistent atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rate-control</arm_group_label>
    <description>Rate-control included AV-nodal blocking agents and AV node ablation with permanent pacing</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible patients enrolled in the original RAFT-AF Study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients previously enrolled and randomized in the RAFT-AF Study that are eligible to&#xD;
        enroll&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Did not participate in the original RAFT-AF Study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fundação Universitária de Cardiologia/Instituto de Cardiologia</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90620-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <investigator>
      <last_name>Tiago Leiria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephen Wilton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>K4A 3B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthew Bennett, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Larry Sterns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Science</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ratika Parkash, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jeff Healey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Damian Redfearn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary's General Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Mary Radyk, RN</last_name>
      <phone>519-749-6578</phone>
      <phone_ext>2503</phone_ext>
      <email>mradyk@smgh.ca</email>
    </contact>
    <investigator>
      <last_name>Umjeet Jolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Science Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Leong-Sit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Pablo Nery, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Eugene Crystal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Andrew Ha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Vidal Essebag, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Lena Rivard, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Univ.cardiologie/pneumologie de Québec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle Nault, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUS Le Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Francois Roux, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mats Jensen-Urstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <investigator>
      <last_name>Chih-Chieh Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Sweden</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Anthony Tang</investigator_full_name>
    <investigator_title>Professor of Medicine, Western University</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>heart failure</keyword>
  <keyword>long-term follow up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

